We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Role of Gefapixant in the Management of Chronic Cough.
- Authors
Anandavelu, Rajarajan; Turner, Alice M.
- Abstract
Chronic cough affects about 10% of the population, and there is a paucity of scientifically approved therapeutic choices. The global burden of chronic cough is underestimated because a significant number of patients do not seek help, yet it has an impact on health-related quality of life and healthcare resource use. In this review, we have defined chronic cough, described the pathophysiology of cough, and critically analysed various therapeutic options, with a particular focus on the first-in-class P2X3 antagonist, gefapixant. The efficacy of gefatpixant is proven in various stages of development, as shown in major trials such as the COUGH-1 (NCT03449134) and COUGH-2 (NCT03449147) studies. The recommended dose for chronic cough is 45 mg twice daily; higher doses have shown side effects, including taste disturbance. Prospects in the management of chronic cough promise various therapeutic options, including newer P2X3 antagonists and other specific agents modulating aspects of the cough reflex pathway.
- Subjects
COUGH treatment; QUALITY of life; CLINICAL trials; MEDICAL care; PUBLIC health
- Publication
touchREVIEWS in Respiratory & Pulmonary Diseases, 2022, Vol 7, Issue 1, p1
- ISSN
2752-549X
- Publication type
Article